Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Early Phase 1

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 1(3)

Early Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03911388Phase 1Recruiting

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Role: collaborator

NCT02574728Phase 2Active Not Recruiting

Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

Role: collaborator

NCT01370330Unknown

131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol

Role: collaborator

NCT06047977Phase 1Recruiting

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Role: collaborator

NCT03893487Early Phase 1Active Not Recruiting

Fimepinostat in Treating Brain Tumors in Children and Young Adults

Role: collaborator

NCT02457845Phase 1Completed

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

Role: collaborator

All 6 trials loaded